Evaluation of oral telmisartan administration as a suppression test for diagnosis of primary hyperaldosteronism in cats.

ABSTRACT:

Background

Development of a telmisartan-based suppression test may facilitate the diagnosis of primary hyperaldosteronism (PHA) in cats, which remains difficult today.

Objectives

To develop a telmisartan suppression test (TST) that is safe, and able to suppress aldosterone secretion in healthy cats but not in cats with PHA.

Animals

Ten healthy cats and 6 cats with PHA.

Methods

Prospective study using a placebo-controlled crossover design to investigate a TST in healthy cats, and evaluation of TST in cats with PHA. Plasma aldosterone concentration, potassium concentration, and systolic blood pressure (SBP) were measured before (T0), and 1 hour (T1) and 1.5 hours after (T1.5) PO administration of 1 mg/kg of telmisartan, 2 mg/kg of telmisartan or placebo.

Resul

SUBMITTER: Fabres V 

PROVIDER: S-EPMC10365039 | biostudies-literature | 2023 Jul-Aug

REPOSITORIES: biostudies-literature